A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
This research is a continuation of an earlier study focusing on Myotonic Dystrophy Type 1 (DM1). Myotonic Dystrophy Type 1 is a condition that causes muscle weakness and other problems. Scientists want to see how safe a new medicine, called VX-670, is when taken for a longer period. They also want to check if it continues to help with the symptoms of DM1 and how the body handles the medicine over time. Only people who have already taken part in a specific previous study involving VX-670 can join this long-term follow-up research.
At a glance
What is this study about?
This study is all about understanding a new medicine called VX-670, which is being developed for people living with Myotonic Dystrophy Type 1, often shortened to DM1. DM1 is a condition that affects muscles, causing them to gradually weaken and making everyday tasks harder. It can also impact other parts of the body.
The main goal of this particular research is to carefully watch what happens when people take VX-670 over a longer period. The researchers want to make sure it's safe and doesn't cause unexpected problems. They're also keen to see if the medicine continues to work well in managing the symptoms of DM1 and how the body processes it over time.
This study is essentially a follow-up for people who have already started treatment with VX-670 in a previous study. By continuing to gather information, doctors and scientists hope to learn more about how this potential new treatment could improve the lives of people with DM1 in the long run.
Key takeaways
- This study is for people already taking the medicine VX-670 for Myotonic Dystrophy Type 1.
- It aims to understand the long-term safety and effects of VX-670.
- Participants must have completed a previous related study.
- The study includes adults aged 18 and over, both men and women.
- This is a Phase 2 study, focused on continued safety and how well the treatment works over time.
Who may be eligible?
To join this study, there are some specific requirements. The most important one is that you must have already taken part in a previous study about the same medicine, VX-670. This previous study was called VX23-670-001.
There are also some things that would prevent you from taking part. For example, if you have any other serious health conditions that are outlined in the study plan, you might not be able to join. These conditions are carefully chosen to make sure the study is safe for everyone involved and that the results are clear.
Overall, the study is open to both men and women who are 18 years old or older. The research team will check all your details carefully to see if this study is right for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Did I already take part in the study called VX23-670-001?
- Am I 18 years old or older?
- Do I have Myotonic Dystrophy Type 1 (DM1)?
- Do I have any other major health issues that might prevent me from joining?
- Have I discussed this study with my doctor?
What does participation involve?
If you are eligible and agree to take part, your involvement would typically include regular visits to a clinic. During these visits, the study team would perform various assessments to check your health, monitor any side effects, and see how the medicine is working. This might involve physical examinations, blood tests, and questionnaires about your symptoms and how you are feeling. You would continue to take the study medicine, VX-670, as directed by the research team. The total duration of your participation would depend on the study's plan, but it's designed to look at the long-term effects of the medication.
Potential risks and benefits
Locations (12)
- Wesley Research InstituteVerified postcodeAuchenflower, Australia
- Neuroscience Clinical Trials Unit, Alfred BrainVerified postcodeMelbourne, Australia
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - PulmonologyVerified postcodeLeuven, Belgium
- Altasciences MontrealVerified postcodeMontreal, Canada
- Montreal Neurological Institute-HospitalVerified postcodeMontreal, Canada
- University of OttawaVerified postcodeOttawa, Canada
- Universite Laval - NeurologyVerified postcodeQuébec, Canada
- Maastricht UMCVerified postcodeMaastricht, Netherlands
- Hospital Universitario y Politecnico La Fe - NeurologyVerified postcodeValencia, Spain
- Queen Elizabeth University Hospital - NeurologyVerified postcodeGlasgow, United Kingdom
- Leonard Wolfson Experimental Neurology Centre CRFVerified postcodeLondon, United Kingdom
- Royal Hallamshire Hospital - NeurologyVerified postcodeSheffield, United Kingdom
Common questions
What is Myotonic Dystrophy Type 1 (DM1)?
DM1 is a condition that causes muscles to weaken over time. It can also affect other parts of the body.
What is VX-670?
VX-670 is the name of the new medicine being tested in this study for DM1.
Which phase is this study in?
This study is in Phase 2, which means researchers are checking the medicine's safety and effectiveness in a larger group of people.
Can anyone with DM1 join this study?
No, you must have already taken part in a specific previous study about VX-670 to be eligible for this one.
How long will the study last?
This is a 'long-term' study, meaning it will track participants over an extended period to monitor the medicine's effects over time.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.